Eryc™ / Erymax™ Capsules
Eryc capsules are a delayed-release erythromycin (a macrolide antibiotic) produced by Mayne Pharma using proprietary pellet technology.
Indicated for the treatment of a wide variety of bacterial infections, Eryc erythromycin is formulated to protect erythromycin degrading in the acidic environment of the stomach, for optimal absorption in the intestine.
Eryc capsules are available in two dose strengths, 250 mg and 333 mg.
Eryc / Erymax erythromycin capsules are currently licensed and sold in Australia, Canada, Sweden and the United Kingdom. In Sweden and the United Kingdom, they are marketed under the trade name Erymax.
Opportunities remain for licensing in a significant number of international territories.